A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
NCT03379584
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
14
Enrollment
INDUSTRY
Sponsor class
Stopped
Due to overall benefit/risk profile
Conditions
Multiple Myeloma
Interventions
DRUG:
SGN-CD48A
Sponsor
Seagen Inc.